These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 21354249)

  • 1. Sustaining GAVI-supported vaccine introductions in resource-poor countries.
    Zuber PL; El-Ziq I; Kaddar M; Ottosen AE; Rosenbaum K; Shirey M; Kamara L; Duclos P
    Vaccine; 2011 Apr; 29(17):3149-54. PubMed ID: 21354249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Introducing new vaccines in the poorest countries: what did we learn from the GAVI experience with financial sustainability?
    Lydon P; Levine R; Makinen M; Brenzel L; Mitchell V; Milstien JB; Kamara L; Landry S
    Vaccine; 2008 Dec; 26(51):6706-16. PubMed ID: 18952134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Global use of Haemophilus influenzae type b conjugate vaccine.
    Ojo LR; O'Loughlin RE; Cohen AL; Loo JD; Edmond KM; Shetty SS; Bear AP; Privor-Dumm L; Griffiths UK; Hajjeh R
    Vaccine; 2010 Oct; 28(43):7117-22. PubMed ID: 20691265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Financial requirements of immunisation programmes in developing countries: a 2004-2014 perspective.
    Peny JM; Gleizes O; Covilard JP
    Vaccine; 2005 Aug; 23(37):4610-8. PubMed ID: 15979769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progress toward introduction of Haemophilus influenzae type b vaccine in low-income countries--worldwide, 2004-2007.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2008 Feb; 57(6):148-51. PubMed ID: 18272957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Developing Countries Vaccine Manufacturers' Network (DCVMN) is a critical constituency to ensure access to vaccines in developing countries.
    Jadhav S; Datla M; Kreeftenberg H; Hendriks J
    Vaccine; 2008 Mar; 26(13):1611-5. PubMed ID: 18294742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Supporting new vaccine introduction decisions: lessons learned from the Hib Initiative experience.
    Hajjeh RA; Privor-Dumm L; Edmond K; O'Loughlin R; Shetty S; Griffiths UK; Bear AP; Cohen AL; Chandran A; Schuchat A; Mulholland EK; Santosham M
    Vaccine; 2010 Oct; 28(43):7123-9. PubMed ID: 20659515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Forecasting demand for Hib-containing vaccine in the world's poorest countries: a 4-year prospective experience.
    Zuber PL; Dumolard L; Shirey M; Rizzo I; Marshall J
    Vaccine; 2009 Jan; 27(3):410-5. PubMed ID: 19013493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Costs of vaccine programs across 94 low- and middle-income countries.
    Portnoy A; Ozawa S; Grewal S; Norman BA; Rajgopal J; Gorham KM; Haidari LA; Brown ST; Lee BY
    Vaccine; 2015 May; 33 Suppl 1():A99-108. PubMed ID: 25919184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lessons learned in shaping vaccine markets in low-income countries: a review of the vaccine market segment supported by the GAVI Alliance.
    Gilchrist SA; Nanni A
    Health Policy Plan; 2013 Dec; 28(8):838-46. PubMed ID: 23174880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Policy analysis: an essential research tool for the introduction of vaccines in developing countries.
    Mahoney R
    J Health Popul Nutr; 2004 Sep; 22(3):331-7. PubMed ID: 15609786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incremental system costs of introducing combined DTwP-hepatitis B-Hib vaccine into national immunization services in Ethiopia.
    Griffiths UK; Korczak VS; Ayalew D; Yigzaw A
    Vaccine; 2009 Feb; 27(9):1426-32. PubMed ID: 19146901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New vaccine adoption: qualitative study of national decision-making processes in seven low- and middle-income countries.
    Burchett HE; Mounier-Jack S; Griffiths UK; Biellik R; Ongolo-Zogo P; Chavez E; Sarma H; Uddin J; Konate M; Kitaw Y; Molla M; Wakasiaka S; Gilson L; Mills A
    Health Policy Plan; 2012 May; 27 Suppl 2():ii5-16. PubMed ID: 22513732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pediatric disease burden and vaccination recommendations: understanding local differences.
    Gentile A; Bhutta Z; Bravo L; Samy AG; Garcia RD; Hoosen A; Islam T; Karimi A; Salem M; Simasathien S; Sohail A; Watanaveeradej V; Wiedenmayer K; Schmitt HJ
    Int J Infect Dis; 2010 Aug; 14(8):e649-58. PubMed ID: 20181506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustainability of National Immunization Programme (NIP) performance and financing following Global Alliance for Vaccines and Immunization (GAVI) support to the Democratic Republic of the Congo (DRC).
    Le Gargasson JB; Breugelmans JG; Mibulumukini B; Da Silva A; Colombini A
    Vaccine; 2013 Apr; 31(15):1886-91. PubMed ID: 23462529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Shaping markets to benefit global health - A 15-year history and lessons learned from the pentavalent vaccine market.
    Malhame M; Baker E; Gandhi G; Jones A; Kalpaxis P; Iqbal R; Momeni Y; Nguyen A
    Vaccine X; 2019 Aug; 2():100033. PubMed ID: 31384748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NTAGI subcommittee recommendations on Haemophilus influenzae type B (Hib) vaccine introduction in India.
    Subcommittee on Introduction of Hib Vaccine in Universal Immunization Program, National Technical Advisory Group on Immunization, India
    Indian Pediatr; 2009 Nov; 46(11):945-54. PubMed ID: 19955578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccine-preventable haemophilus influenza type B disease burden and cost-effectiveness of infant vaccination in Indonesia.
    Gessner BD; Sedyaningsih ER; Griffiths UK; Sutanto A; Linehan M; Mercer D; Mulholland EK; Walker DG; Steinhoff M; Nadjib M
    Pediatr Infect Dis J; 2008 May; 27(5):438-43. PubMed ID: 18398383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An analysis of how the GAVI alliance and low- and middle-income countries can share costs of new vaccines.
    Saxenian H; Cornejo S; Thorien K; Hecht R; Schwalbe N
    Health Aff (Millwood); 2011 Jun; 30(6):1122-33. PubMed ID: 21653966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of a measles, mumps, rubella and varicella vaccine given with combined Haemophilus influenzae type b conjugate/hepatitis B vaccines and combined diphtheria-tetanus-acellular pertussis vaccines.
    Shinefield H; Black S; Thear M; Coury D; Reisinger K; Rothstein E; Xu J; Hartzel J; Evans B; Digilio L; Schödel F; Brown ML; Kuter B;
    Pediatr Infect Dis J; 2006 Apr; 25(4):287-92. PubMed ID: 16567978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.